PYRIMIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA-1-ANTITRYPSIN DEFICIENCY

(19)

(11)

EP 3 894 393 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	15.02.2023 Bulletin 2023/07

(45)	Mention of the grant of the patent:
	21.12.2022 Bulletin 2022/51

(21)	Application number: 19835312.0

(22)	Date of filing: 13.12.2019

(51)

International Patent Classification (IPC):

C07D 239/36^(1974.07)
A61P 1/16^(2000.01)
A61P 11/08^(2000.01)

A61K 31/513^(2000.01)
A61P 11/06^(2000.01)

(52)	Cooperative Patent Classification (CPC):
	C07D 239/36; A61P 11/06; A61P 11/08; A61P 1/16; A61K 31/513

(86)	International application number:
	PCT/GB2019/053552

(87)	International publication number:
	WO 2020/120992 (18.06.2020 Gazette 2020/25)

(54)	PYRIMIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA-1-ANTITRYPSIN DEFICIENCY PYRIMIDONE VERBINDUNGEN UND DEREN VERWENDUNG ZUR BEHANDLUNG VON ALPHA-1-ANTITRYPSIN-MANGEL COMPOSÉS DE PYRIMIDONE ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE DÉFICIENCE EN ALPHA-1-ANTITRYPSINE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Validation States:
	MA

(30)

Priority:

14.12.2018 GB 201820450

(43)	Date of publication of application:
	20.10.2021 Bulletin 2021/42

(73)	Proprietor: Z Factor Limited
	Altrincham Cheshire WA14 2DT (GB)

(72)	Inventors:
	RAMSDEN, Nigel Babraham, Cambridge CB22 3FH (GB) FOX, David John Coventry CV4 7AL (GB) HUNTINGTON, James Andrew Altrincham, Cheshire WA14 2DT (GB)

(74)	Representative: Roberts, Michael Austin
	Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS London E1 8QS (GB)

(56)

References cited: :

WO-A2-01/52830
US-A1- 2015 045 344

WO-A2-2008/143633

MEERA MALLYA ET AL: "Small Molecules Block the Polymerization of Z [alpha] 1 -Antitrypsin and Increase the Clearance of Intracellular Aggregates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 22, 1 November 2007 (2007-11-01), pages 5357-5363, XP55667904, US ISSN: 0022-2623, DOI: 10.1021/jm070687z
MARION BOUCHECAREILH ET AL: "Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of [alpha]1-Antitrypsin Deficiency", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 45, 2 November 2012 (2012-11-02), pages 38265-38278, XP55667908, US ISSN: 0021-9258, DOI: 10.1074/jbc.M112.404707

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).